The content on this site is intended for healthcare professionals only
At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Axel Hauschild presented data from a Phase III multicenter clinical trial that found treatment with the investigational BRAF-targeted drug dabrafenib reduced the risk of disease progression by 70 percent compared to standard dacarbazine chemotherapy in patients with previously untreated, advanced melanoma with mutations in the BRAF gene.
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in head and neck cancer treatment in India
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Advancements in paediatric Acute lymphoblastic leukemia management
Enhancing head and neck oncology: Key insights from the conference
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Choosing 1st line TKI Wisely in patients with CML
Choosing Wisely in endometrial & cervix cancers: Medical therapy
